

FOI 3747

15th May 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in total regardless of diagnosis with the following drugs between 1st Jan 2026 and 31st March 2026, or the latest 3-month period for which you have data?

Drug Name	<u>Total</u> number of patients treated <u>regardless of diagnosis</u>
Adalimumab	
Etrasimod	
Filgotinib	
Golimumab	
Guselkumab	
Infliximab (Biosimilars)	
Infliximab (Remicade)	
Mirikizumab	
Ozanimod	
Risankizumab	
Tofacitinib	
Upadacitinib	
Ustekinumab	
Vedolizumab	

Response: Patient Data as of 06/05/2026:

Drug Name	<u>Total</u> number of patients treated <u>regardless of diagnosis</u>
Adalimumab	1272
Etrasimod	0
Filgotinib	0
Golimumab	77
Guselkumab	85
Infliximab (Biosimilars)	173
Infliximab (Remicade)	<5*

Mirikizumab	5
Ozanimod	0
Risankizumab	163
Tofacitinib	9
Upadacitinib	147
Ustekinumab	139
Vedolizumab	127

*The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Q2. How many patients were treated by the Gastroenterology Department or Clinic with the following drugs between 1st Jan 2026 and 31st March 2026, or the latest 3-month period for which you have data?

Drug Name	Number of patients treated by the <u>Gastroenterology Department</u>
Adalimumab	
Etrasimod	
Filgotinib	
Golimumab	
Guselkumab	
Infliximab (Biosimilars)	
Infliximab (Remicade)	
Mirikizumab	
Ozanimod	
Risankizumab	
Tofacitinib	
Upadacitinib	
Ustekinumab	
Vedolizumab	

Response:

Drug Name	Number of patients treated by the <u>Gastroenterology Department</u>
Adalimumab	203
Etrasimod	0
Filgotinib	0
Golimumab	<5*
Guselkumab	0
Infliximab (Biosimilars)	132
Infliximab (Remicade)	0
Mirikizumab	5
Ozanimod	0
Risankizumab	19
Tofacitinib	<5*
Upadacitinib	51
Ustekinumab	110
Vedolizumab	127

*The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Q3. How many patients with Crohn's Disease or Ulcerative Colitis, in total regardless of department / clinic, were treated with the following drugs between 1st Jan 2026 and 31st March 2026, or the latest 3-month period for which you have data?

Drug Name	Number patients with	Number patients with
	<u>Crohn's Disease</u>	<u>Ulcerative Colitis</u>
Adalimumab		
Etrasimod		
Filgotinib		

Golimumab		
Guselkumab		
Infliximab (Biosimilars)		
Infliximab (Remicade)		
Mirikizumab		
Ozanimod		
Risankizumab		
Tofacitinib		
Upadacitinib		
Ustekinumab		
Vedolizumab		

Response:

Drug Name	Number patients with	Number patients with
	<u>Crohn's Disease</u>	<u>Ulcerative Colitis</u>
Adalimumab	136	67
Etrasimod	0	0
Filgotinib	0	0
Golimumab	0	<5*
Guselkumab	0	0
Infliximab (Biosimilars)	66	65
Infliximab (Remicade)	0	0
Mirikizumab	<5*	<5*
Ozanimod	0	0
Risankizumab	0	0
Tofacitinib	0	<5*
Upadacitinib	30	21
Ustekinumab	71	39
Vedolizumab	60	67

*The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they

would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

END